A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

Inclusion criteria

• The participant has a diagnosis of migraine as defined by ICHD-3 guidelines confirmed at the Screening Visit.
• The participant has a history of migraine onset ≥12 months prior to the Screening Visit.
• The participant has ≥2 migraine days and headache occurring on <15 days per month for each month within the past 3 months prior to the Screening Visit.
• The participant has a body mass index (BMI) ≥18.5 and ≤ 35 kilograms per meter squared (kg/m^2) at the Screening Visit.

Exclusion criteria

• The participant has previously been dosed with an anti-pituitary adenylate cyclase-activating peptide (PACAP) treatment.
• The participant has participated in a clinical trial <30 days prior to the Screening Visit.
• The participant has taken any investigational medicinal product (IMP) <3 months or <5 half-lives of that product, whichever is longer, prior to Visit 1.
• The participant is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not willing to use adequate contraceptive methods.
• The participant has known or suspected hypersensitivity or intolerance to the IMP, auxiliary medicinal product (AxMP), or their excipients.

Note: Other inclusion and exclusion criteria may apply.